{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia3cvppg6bwb46eygwknbnzgjy64iaxfwbxkchcrfbmoxzk7utmz4",
    "uri": "at://did:plc:tpd4fxsnyhzzhnj6g4llqsfn/app.bsky.feed.post/3mijwgjuxx7b2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifv5wacwdcyhj5qilsz234lzf6ohxqghujlbjrzkkuy5yvbsrjwxa"
    },
    "mimeType": "image/jpeg",
    "size": 24844
  },
  "path": "/news/11752953/common-antidepressant-may-help-adults-long-covid/",
  "publishedAt": "2026-04-02T18:38:47.000Z",
  "site": "https://globalnews.ca",
  "tags": [
    "Canada",
    "Health",
    "Fluvoxamine",
    "long covid"
  ],
  "textContent": "The clinical trial showed a 99 per cent probability that fluvoxamine outperformed placebo for 'reducing fatigue severity and improving quality of life in people with long COVID.'",
  "title": "Common antidepressant may help adults with long COVID: study"
}